NICE, SIGN, and ADA-EASD Dr Seidu said most clinicians in the diabetes sector will be able to cope with the differences in European and UK guidelines for now. "It's a European guideline. And we're still in Europe despite Brexit. So we will follow it for those who know about it. "...
In draft guidance, NICE rejectedocrelizumab (Ocrevus, Roche)for treating early primary progressive multiple sclerosis (MS) with imaging features characteristic of inflammatory activity in adults. It said clinical trial results show that ocrelizumab can slow the worsening of disability in people with the...
Commenting on the decision, Ropinder Gill, CEO of the charityLymphoma Action, said: "We know only too well the impact that relapsing follicular lymphoma has on people and their families, which is why there is always a need for additional treatment options that will help those who have the m...